CompletedEUCTR 2006-001475-38
A DOUBLE BLIND, PLACEBO CONTROLLED, RANDOMIZED, SEQUENTIAL GROUP, MULTIPLE DOSE STUDY OF THE EFFICACY OF THE CRF1-RECEPTOR ANTAGONIST R317573 ON CCK-4 INDUCED ANXIETY IN HEALTHY MALE SUBJECTS.
This historical record does not confirm current site availability.
Historical research recordNetherlands
Understand this study
What did researchers investigate?
This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments. Check the source details below for country statuses and any transfer to CTIS.
- Listed locations
- Netherlands
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
Study information
Study start dateNot clearly listed
- Recruitment status
- Completed
- Enrollment listed in the registry
- 72
- Sponsor
- Janssen Cliag Ltd. C/O Johnson & Johnson PRD
- Sponsor type
- Other organization
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
- Locations
- Netherlands
- Age range
- Not clearly listed
- Official registry ID
- EUCTR 2006-001475-38
- Official title
Show the full official title
A DOUBLE BLIND, PLACEBO CONTROLLED, RANDOMIZED, SEQUENTIAL GROUP, MULTIPLE DOSE STUDY OF THE EFFICACY OF THE CRF1-RECEPTOR ANTAGONIST R317573 ON CCK-4 INDUCED ANXIETY IN HEALTHY MALE SUBJECTS.
Recruitment & locations
CompletedNetherlands
Registry details
Historical country statuses
- Netherlands — Completed
Questions about this study
Who is behind this study?
The study sponsor is Janssen Cliag Ltd. C/O Johnson & Johnson PRD.
Want to find a study that may fit you better?
Answer a few simple questions to explore HopeStage studies by condition, country, and situation.
Find a study that may fit meRelated studies
A randomized, double blind, placebo-controlled crossover study to investigate the effects of a selective serotonergic reuptake inhibitor on resting state fMRI in healthy volunteers.
A Working Memory Training to Decrease Rumination in Depressed and Anxious Individuals
